我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
0
0 进行中
药物批准
344
批准总数
监管机构
5
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
NMPA
National Medical Products Administration
FDA
Food and Drug Administration
244
PHILIPPINES
Philippines FDA
38
SFDA
Saudi Food and Drug Authority
42
NPRA
National Pharmaceutical Regulatory Agency
15
- Gland Pharma Limited secured FDA approval for its generic version of olopatadine hydrochloride 0.7% ophthalmic solution, equivalent to Alcon's Pataday Once Daily Extra Strength. - The over-the-counter eye drops treat ocular itching associated with allergic conjunctivitis and provide 24-hour relief with once-daily dosing. - This approval marks the second generic version of a Pataday formulation to receive FDA clearance, following Glenmark's approval for the 0.2% concentration in 2025. - The company's shares gained 0.99% following the announcement, reflecting investor confidence in Gland Pharma's expanding ophthalmic portfolio.
